Dr Reddy's Lab
Here's why Vinay Rajani is bullish on Dr Reddy's, Oracle Financial Services
As per the technical analyst, the Budget session high of 17,973 and low of 17,353 have become crucial levels to watch out for any directional move in the Nifty index
 "Here's why Vinay Rajani is bullish on Dr Reddy's, Oracle Financial Services")
Sensex slumps 774 pts, Nifty ends below 17900; Auto, FMCG stocks outshine
Stock market LIVE: As per rollover data, the Nifty index has, so far, witnessed rollover in-line with the last three months' averages. However, slight declines in roll cost indicates a capped upside
 "Sensex slumps 774 pts, Nifty ends below 17900; Auto, FMCG stocks outshine")
Dr Reddy's Laboratories inks agreement to acquire Nimbus Health GmbH
Dr Reddy's Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH. The drug major said it has entered into a definitive agreement to acquire the company which is a privately owned, licensed pharmaceutical wholesaler focusing on medical cannabis in Germany. Dr Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone-based earn-outs over the next four years, the Hyderabad-based drug maker said in a regulatory filing. The company however did not share financial details. The acquisition will allow Dr Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, it added. "Medical cannabis is increasingly used to address and treat high unmet medical needs, especially in pain management and CNS. Further, with numerous studies being conducted to leverage and introduce medical cannabis, we believe this is a must-be field for future healthcare
 "Dr Reddy's Laboratories inks agreement to acquire Nimbus Health GmbH")
Dr Reddy's Lab Q3 results: Net profit soars over 25 times to Rs 707 cr
Revenues stood at Rs 5,319.7 crore during the third quarter as compared with Rs 4,929.6 crore in the same period of 2020-21
 "Dr Reddy's Lab Q3 results: Net profit soars over 25 times to Rs 707 cr")
Consignment of 3 mn Sputnik V vaccine from Russia land in Hyderabad
A consignment, comprising as many as three million doses of Russia's COVID-19 vaccine Sputnik V, landed at the Rajiv Gandhi International Airport
 "Consignment of 3 mn Sputnik V vaccine from Russia land in Hyderabad")
Dr Reddy's inks pact with Gilead to manufacture, market Remdesivir in India
Dr Reddy's would need to scale up manufacturing and obtain regulatory approval for marketing of this drug in respective countries, the company said
 "Dr Reddy's inks pact with Gilead to manufacture, market Remdesivir in India")
Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad
According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact
 "Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad")
Dr Reddy's gets USFDA EIR for Vizag plant; inspection not concluded yet
In March this year, Dr Reddy's Laboratories had received observations from the US regulator for its Duvvada facility
 "Dr Reddy's gets USFDA EIR for Vizag plant; inspection not concluded yet")
Duvvada unit audit: Dr Reddy's to launch corrective plan post verdict
Hyderabad, 8 September: Sending the remediation steps of Dr Reddy's Laboratories Limited for a toss, German Regulatory Authory has issued six major audit observations on the company's Duvvada formulations manufacturing plant, months after the US Food and Drug Administration(US FDA) slapped the facility with Form 483 with the highest number of 13 observations in a re-inspection sought by the company.This is the second instance where Dr Reddy's manufacturing facility has fallen short of quality compliances during a month's time. The German regulatory body had told the company last month that it was not going to renew the compliance certification of Unit 2 at Bachupally in Hyderabad, thus effectively halting the product exports to the EU member countries from that plant.There are no immediate financial implications from the latest regulatory action as Duvvada facility already stopped exporting any product to Europe.The development, however, raised serious doubts over the effectiveness ..
 "Duvvada unit audit: Dr Reddy's to launch corrective plan post verdict")
Dr Reddy's launches schizophrenia drug in the US market
Aripiprazole is a therapeutic equivalent generic version of Ablify tablets in the US market
 "Dr Reddy's launches schizophrenia drug in the US market")
Dr Reddy's enters Dow Jones Indices
Company recognised for its corporate sustainability leadership, is sole pharma firm in index of emerging markets
Dr Reddy's to buy eight ANDAs in US for $350 million
ANDAs comprise of complex generic products across diverse dosage forms
 "Dr Reddy's to buy eight ANDAs in US for $350 million")
Dr Reddy's buyback to cushion downside
Most important positive for the stock will be the resolution of the US inspector issues
 "Dr Reddy's buyback to cushion downside")
